POS0271 INFLIXIMAB FOR PARENCHYMAL NEURO-BEHÇET’S SYNDROME: A META-ANALYSIS

英夫利昔单抗 医学 病理 疾病
作者
Wenjie Zheng,Xiao Wang,Yan Liu,Yiyuan Ao,Jinling Wang,J. Liu,Yan Xu
标识
DOI:10.1136/annrheumdis-2024-eular.2748
摘要

Background:

Behçet's syndrome (BS) is a chronic, recurrent systemic vasculitis that can affect multiple systems. Neuro-Behçet's syndrome (NBS), especially parenchymal NBS(p-NBS), results in severe neurological sequelae with poor prognosis, ranging from cognitive changes to paralysis, which remains a challenging clinical issue.

Objectives:

This study aimed to evaluate the efficacy and safety of infliximab (IFX), a type of anti-TNF-α agents, in treating patients with p-NBS and hopefully provide a detailed time analysis for the IFX effect timeline in NBS treatment.

Methods:

We conducted this meta-analysis following the PRISMA guidelines. PubMed, Embase, Cochrane Library and Web of Science were systematically searched using the following logics: Behçet's syndrome (all synonyms) AND Infliximab (all synonyms) AND ('neuro' OR 'neurological' OR 'neurologic), and we also included the data from our institution in this meta-analysis. Therapeutic efficacy was evaluated by the improvement of clinical symptoms and radiological lesions, and clinical improvement was specifically defined as complete remission (CR), partial remission (PR) and no response (NR) [1,2]. We evaluated the efficacy of IFX at 3, 6, and 12 months respectively. The results were presented as forest plots with 95% confidence intervals. Besides, the details of adverse drug reactions were recorded.

Results:

8 studies involving a total of 77 patients were identified to perform the meta-analysis by adding the results from our institution. The pooled efficacy of IFX in treating p-NBS patients were analyzed. Clinical complete remission was achieved in 14.7% (95%CI 0.00-83.5%) of patients at Month 3, 28.7% (95% CI 0.00-86.7%) of patients at Month 6, 54.4% (95%CI 13.9-92.3%) at Month 12. Clinical partial remission was achieved in 97.0% (95%CI 61.9-100%) of patients at Months 3, 89.6% (95%CI 45.9-100%) of patients at Months 6, 100.0% (95%CI 96.0-100%) at Months 12. MRI improvement was achieved in 100.0% (95%CI 89.7-100%) of patients at Month 3, 89.1% (95% CI 26.3-100%) of patients at Month 6, 99.5% (95% CI 96.0-100%) at Month 12. The time-phase analysis indicated that IFX exerted its effect within 3 months and was sustained during the long term. Safety information was reported in 16 patients. Among them, 9% of patients experienced severe adverse events (AEs), no AE-related deaths were reported.

Conclusion:

IFX is an effective treatment option for p-NBS, and the incidence of severe AEs was acceptable. A comprehensive evaluation should be performed after three months of medication to determine the need for adjustments in subsequent therapy. Further well-designed, large-scale RCTs are needed to verify our findings.

REFERENCES:

[1] Hibi T, Hirohata S, Kikuchi H, et al. Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study. Medicine (Baltimore) 2016;95:e3863. [2] Pipitone N, Olivieri I, Padula A, et al. Infliximab for the treatment of neuro-Behçet's disease: A case series and review of the literature. Arthritis Care and Research 2008;59:285-90. (Article).

Acknowledgements:

We thank all the participants and their families.

Disclosure of Interests:

None declared.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
fomo完成签到,获得积分10
1秒前
nagi发布了新的文献求助10
4秒前
jfeng完成签到,获得积分10
6秒前
JN完成签到,获得积分10
14秒前
忐忑的书桃完成签到 ,获得积分10
15秒前
qaplay完成签到 ,获得积分0
15秒前
友好语风完成签到,获得积分10
16秒前
CLTTTt完成签到,获得积分10
17秒前
yk完成签到,获得积分10
19秒前
甜美的初蓝完成签到 ,获得积分10
23秒前
早安完成签到 ,获得积分10
27秒前
初昀杭完成签到 ,获得积分10
31秒前
量子星尘发布了新的文献求助10
33秒前
LIU完成签到 ,获得积分10
33秒前
35秒前
nianshu完成签到 ,获得积分0
36秒前
starwan完成签到 ,获得积分10
37秒前
松松发布了新的文献求助20
37秒前
hooddy123459发布了新的文献求助10
38秒前
wenhuanwenxian完成签到 ,获得积分10
42秒前
happy完成签到 ,获得积分10
46秒前
拾壹完成签到,获得积分10
54秒前
雪花完成签到,获得积分10
56秒前
清风完成签到 ,获得积分10
56秒前
雪花发布了新的文献求助10
1分钟前
秀丽笑容完成签到 ,获得积分10
1分钟前
江湖应助聪慧芷巧采纳,获得10
1分钟前
量子星尘发布了新的文献求助10
1分钟前
Rjy完成签到 ,获得积分10
1分钟前
性感母蟑螂完成签到 ,获得积分10
1分钟前
ruochenzu完成签到,获得积分10
1分钟前
陈尹蓝完成签到 ,获得积分10
1分钟前
天道酬勤完成签到,获得积分10
1分钟前
1分钟前
仁爱的谷南完成签到,获得积分10
1分钟前
雯雯完成签到 ,获得积分10
1分钟前
一路有你完成签到 ,获得积分10
1分钟前
1分钟前
ruochenzu发布了新的文献求助10
1分钟前
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038066
求助须知:如何正确求助?哪些是违规求助? 3575779
关于积分的说明 11373801
捐赠科研通 3305584
什么是DOI,文献DOI怎么找? 1819239
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022